Oncternal Therapeutics (ONCT)
(Delayed Data from NSDQ)
$8.20 USD
-0.79 (-8.79%)
Updated Jun 7, 2024 03:51 PM ET
After-Market: $8.79 +0.59 (7.20%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
Oncternal Therapeutics, Inc. [ONCT]
Reports for Purchase
Showing records 21 - 33 ( 33 total )
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ROR1 Collaboration Inked With Celularity; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updated Cirmtuzumab MCL Results at ASH; 2Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cirmtuzumab + Ibrutinib Continues to Deliver Benefit in MCL; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Upcoming ASCO Conference Data Presentations; 1Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Favorable Data for Cirmtuzumab + Paclitaxel in Breast Cancer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cirmtuzumab Marches On; 2020 Financials Reported; Raising PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Two Agreements Inked Related to ROR1-Targeted Cellular Therapy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Balance Sheet Comprehensively Strengthened; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
VelosBio Acquired for $2.75B in Cash; 3Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TK216 Gets Rare Pediatric Disease Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Runway Extended; VelosBio Gets Orphan Drug Status in MCL; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Conquering Cancer With Cirmtuzumab; Initiating at Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R